查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1954269

動物用抗生素和抗菌藥物市場分析及預測（至2035年）：類型、產品類型、應用、劑型、最終用戶、技術、功能、階段

Animal Antibiotics and Antimicrobials Market Analysis and Forecast to 2035: Type, Product, Application, Form, End User, Technology, Functionality, Stage
出版日期: | 出版商: Global Insight Services | 英文 303 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

獸用抗生素和抗菌藥物市場預計將從2024年的7.214億美元成長到2034年的9.8億美元，複合年成長率約為3.4%。獸用抗生素和抗菌藥物市場涵蓋用於預防、控制和治療牲畜和伴侶動物感染疾病的藥物。市場的成長動力源自於保障動物健康和最佳化農業生產力的需求。法規結構和日益成長的抗菌素抗藥性問題正在影響市場動態，促使人們開發替代療法並制定合理的用藥指南。

受對高效獸醫保健解決方案日益成長的需求推動，獸用抗生素和抗菌藥物市場正經歷強勁成長。飼料添加劑領域已成為成長最快的細分市場，這主要得益於提高牲畜生產力和健康狀況的需求。在該領域，四環黴素和青黴素類藥物因其頻譜抗菌活性和成本效益而特別突出。治療領域緊隨其後，口服和注射劑型因其能夠精準治療特定感染疾病而備受青睞。離子載體和大環內酯類藥物也因其在預防疾病傳播和促進動物生長方面的作用而得到更廣泛的應用。隨著水產品消費量的成長，對疾病控制的需求也日益增加，水產養殖業預計將顯著擴張。此外，向永續和負責任的抗生素使用方式的轉變，也為益生菌和益生元等替代解決方案的創新創造了機會。這些趨勢凸顯了市場的動態特性，並顯示新興技術和產品開發領域存在潛在的策略投資機會。

市場區隔
種類 四環黴素、青黴素類、大環內酯類、Aminoglycosides、磺胺類藥物、Fluoroquinolones、林可醯胺類、頭孢菌素類
產品 飼料添加劑、注射、口服粉末、口服液、乳房內製劑、預混合料
目的 家禽、豬、牛、水產養殖、伴侶動物
形式 液體、粉末、顆粒
最終用戶 獸醫診所、畜牧場、研究機構
科技 離子載體，BETA-內醯胺類
功能 抗發炎、抗寄生蟲
步 生長促進劑和治療劑

獸用抗生素和抗菌藥物市場呈現出動態的市場格局，主要參與者佔了相當大的市場。定價策略競爭激烈，反映出市場對高效能獸藥解決方案的持續需求。新產品頻繁上市，其驅動力在於創新需求和應對不斷出現的動物健康問題。市場正朝著更永續、更環保的抗菌藥物方向發展，這與全球負責任的畜牧業趨勢相符。競爭基準研究表明，老字型大小企業透過策略聯盟和收購來保持其優勢，佔據著強大的市場地位。監管影響顯著，嚴格的指導方針規範產品開發和市場准入。歐洲和北美高度監管的市場正在影響市場成長軌跡。在亞太和拉丁美洲等新興市場，不斷成長的牲畜數量和日益增強的動物健康意識創造了盈利的機會。技術進步和監管合規正在推動創新和擴張，使市場前景充滿希望。

主要趨勢和促進因素：

由於人們對動物健康的日益關注以及全球肉類消費量的成長，獸用抗生素和抗菌藥物市場正經歷顯著成長。市場趨勢表明，畜牧業正朝著預防性醫療保健的方向發展，凸顯了抗生素和抗菌藥物在保障動物福利和生產力方面的重要性。對高品質肉類和乳製品的需求推動了對有效疾病控制解決方案的需求。獸醫領域的科技創新正在促進新型抗生素和抗菌藥物的研發，從而提高療效和安全性。法規結構也在不斷發展，更加重視產品的永續和負責任使用，這刺激了創新。此外，精準畜牧養殖技術的應用正在改善動物健康的監測和管理，進一步推動市場成長。新興市場存在著許多機遇，畜牧業的擴張正是為了因應不斷變化的飲食習慣。能夠提供經濟高效解決方案的公司有望佔據可觀的市場佔有率。此外，製藥公司與研究機構之間的合作正在加速發現新的化合物，以應對日益嚴重的抗菌素抗藥性問題。隨著相關人員將動物健康和食品安全放在首位，預計該市場將持續成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 四環黴素
    • 青黴素
    • 大環內酯類
    • Aminoglycosides
    • 磺胺類藥物
    • Fluoroquinolones
    • 林可醯胺類
    • 頭孢菌素
  • 市場規模及預測：依產品分類
    • 飼料添加劑
    • 注射
    • 口服粉劑
    • 口服液
    • 乳房內製劑
    • 預混合料
  • 市場規模及預測：依應用領域分類
    • 家禽
    • 豬
    • 牛
    • 水產養殖
    • 伴侶動物
  • 市場規模及預測：依類型
    • 液體
    • 粉末
    • 顆粒
  • 市場規模及預測：依最終用戶分類
    • 獸醫診所
    • 畜牧場
    • 研究所
  • 市場規模及預測：依技術分類
    • 離子載體
    • BETA-內醯胺類
  • 市場規模及預測：依功能分類
    • 抗發炎藥
    • 抗寄生蟲藥物
  • 市場規模及預測：依發展階段分類
    • 生長促進劑
    • 治療藥物

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Phibro Animal Health
  • Eco Animal Health
  • Huvepharma
  • Norbrook Laboratories
  • HIPRA
  • Vetoquinol
  • Ceva Animal Health
  • Kyoritsu Seiyaku
  • Dechra Pharmaceuticals
  • Zagro
  • Virbac
  • Biogenesis Bago
  • Lohmann Animal Health
  • Neogen Corporation
  • Biovet
  • Elanco Animal Health
  • Boehringer Ingelheim Vetmedica
  • Vetanco
  • Merial
  • Bimeda

第9章：關於我們

簡介目錄
Product Code: GIS20983

Animal Antibiotics and Antimicrobials Market is anticipated to expand from $721.4 million in 2024 to $980.0 million by 2034, growing at a CAGR of approximately 3.4%. The Animal Antibiotics and Antimicrobials Market encompasses pharmaceutical products designed to prevent, control, and treat infections in livestock and companion animals. This market is driven by the need to ensure animal health and optimize agricultural productivity. Regulatory frameworks and rising concerns over antimicrobial resistance are shaping market dynamics, prompting innovations in alternative therapies and prudent usage guidelines.

The Animal Antibiotics and Antimicrobials Market is experiencing robust growth, propelled by the escalating demand for effective veterinary healthcare solutions. The feed additives segment emerges as the top-performing sub-segment, driven by the need to enhance livestock productivity and health. Within this segment, tetracyclines and penicillins are particularly prominent, owing to their broad-spectrum efficacy and cost-effectiveness. The therapeutic segment trails closely, with oral and injectable formulations gaining traction for their precision in treating specific infections. Ionophores and macrolides are also witnessing increased adoption, reflecting their role in preventing disease spread and promoting growth in animals. The aquaculture sector is poised for significant expansion, as rising seafood consumption necessitates enhanced disease management. Furthermore, the shift towards sustainable and responsible antibiotic use presents opportunities for innovation in alternative solutions, such as probiotics and prebiotics. These trends underscore the market's dynamic nature, highlighting the potential for strategic investments in emerging technologies and product development.

Market Segmentation
TypeTetracyclines, Penicillins, Macrolides, Aminoglycosides, Sulfonamides, Fluoroquinolones, Lincosamides, Cephalosporins
ProductFeed Additives, Injectable, Oral Powders, Oral Solutions, Intramammary Preparations, Premixes
ApplicationPoultry, Swine, Cattle, Aquaculture, Companion Animals
FormLiquid, Powder, Granules
End UserVeterinary Clinics, Animal Farms, Research Institutes
TechnologyIonophore, Beta-lactam
FunctionalityAnti-inflammatory, Antiparasitic
StageGrowth Promoters, Therapeutics

The Animal Antibiotics and Antimicrobials Market demonstrates a dynamic landscape characterized by significant market share distribution among key players. Pricing strategies are competitive, reflecting the ongoing demand for effective veterinary solutions. New product launches are frequent, driven by innovation and the necessity to address emerging animal health concerns. The market is witnessing a shift towards more sustainable and eco-friendly antimicrobials, aligning with global trends in responsible animal husbandry. Competition benchmarking reveals a robust presence of established companies striving to maintain their dominance through strategic partnerships and acquisitions. Regulatory influences are substantial, with stringent guidelines shaping product development and market entry. The European and North American markets are heavily regulated, impacting growth trajectories. Emerging markets in Asia-Pacific and Latin America present lucrative opportunities due to increasing livestock populations and rising awareness of animal health. The market's future is promising, with technological advancements and regulatory compliance driving innovation and expansion.

Geographical Overview:

The animal antibiotics and antimicrobials market is witnessing notable growth across various regions, each exhibiting unique dynamics. North America holds a prominent position, driven by the extensive use of antibiotics in livestock and stringent regulatory frameworks. The region's focus on food safety and animal health further propels market expansion. Europe follows closely, with a strong emphasis on reducing antibiotic use in agriculture, fostering the development of alternative solutions. Asia Pacific is experiencing rapid growth due to increasing livestock production and rising awareness of animal health. Countries like China and India are emerging as significant contributors to market dynamics, with substantial investments in veterinary healthcare. In Latin America, the market is expanding as countries like Brazil and Argentina focus on enhancing livestock productivity. Meanwhile, the Middle East & Africa present untapped potential, with growing recognition of the importance of antibiotics and antimicrobials in improving animal health and productivity.

Global tariffs on animal antibiotics and antimicrobials are prompting strategic pivots in Japan, South Korea, China, and Taiwan. Japan and South Korea are enhancing domestic production capabilities to mitigate reliance on imports, while China accelerates its self-sufficiency drive amidst geopolitical tensions. Taiwan, with its robust pharmaceutical sector, remains pivotal but vulnerable to regional conflicts. The parent market is experiencing steady growth globally, driven by rising livestock production and heightened awareness of antimicrobial resistance. By 2035, the market is expected to evolve towards sustainable practices, with a focus on alternative solutions. Middle East conflicts contribute to volatility in energy prices, indirectly affecting supply chain costs and operational efficiencies, necessitating strategic adaptations to ensure resilience in this critical sector.

Key Trends and Drivers:

The Animal Antibiotics and Antimicrobials Market is experiencing notable growth due to rising awareness of animal health and increasing global meat consumption. Market trends reveal a shift towards preventive healthcare for livestock, emphasizing the importance of antibiotics and antimicrobials to ensure animal welfare and productivity. The demand for high-quality meat and dairy products is driving the need for effective disease management solutions. Technological advancements in veterinary medicine are fostering the development of novel antibiotics and antimicrobials, enhancing treatment efficacy and safety. Regulatory frameworks are evolving, focusing on sustainable and responsible use of these products, which is stimulating innovation. Moreover, the integration of precision livestock farming techniques is enabling better monitoring and management of animal health, further propelling market growth. Opportunities abound in emerging markets where livestock production is expanding to meet dietary shifts. Companies that can offer cost-effective and efficient solutions are poised to capture significant market share. Additionally, collaborations between pharmaceutical firms and research institutions are accelerating the discovery of new compounds, addressing the growing concern of antimicrobial resistance. This market is set for sustained expansion as stakeholders prioritize animal health and food security.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Application
  • 2.4 Key Market Highlights by Form
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Technology
  • 2.7 Key Market Highlights by Functionality
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Tetracyclines
    • 4.1.2 Penicillins
    • 4.1.3 Macrolides
    • 4.1.4 Aminoglycosides
    • 4.1.5 Sulfonamides
    • 4.1.6 Fluoroquinolones
    • 4.1.7 Lincosamides
    • 4.1.8 Cephalosporins
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Feed Additives
    • 4.2.2 Injectable
    • 4.2.3 Oral Powders
    • 4.2.4 Oral Solutions
    • 4.2.5 Intramammary Preparations
    • 4.2.6 Premixes
  • 4.3 Market Size & Forecast by Application (2020-2035)
    • 4.3.1 Poultry
    • 4.3.2 Swine
    • 4.3.3 Cattle
    • 4.3.4 Aquaculture
    • 4.3.5 Companion Animals
  • 4.4 Market Size & Forecast by Form (2020-2035)
    • 4.4.1 Liquid
    • 4.4.2 Powder
    • 4.4.3 Granules
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Veterinary Clinics
    • 4.5.2 Animal Farms
    • 4.5.3 Research Institutes
  • 4.6 Market Size & Forecast by Technology (2020-2035)
    • 4.6.1 Ionophore
    • 4.6.2 Beta-lactam
  • 4.7 Market Size & Forecast by Functionality (2020-2035)
    • 4.7.1 Anti-inflammatory
    • 4.7.2 Antiparasitic
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Growth Promoters
    • 4.8.2 Therapeutics

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Application
      • 5.2.1.4 Form
      • 5.2.1.5 End User
      • 5.2.1.6 Technology
      • 5.2.1.7 Functionality
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Application
      • 5.2.2.4 Form
      • 5.2.2.5 End User
      • 5.2.2.6 Technology
      • 5.2.2.7 Functionality
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Application
      • 5.2.3.4 Form
      • 5.2.3.5 End User
      • 5.2.3.6 Technology
      • 5.2.3.7 Functionality
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Application
      • 5.3.1.4 Form
      • 5.3.1.5 End User
      • 5.3.1.6 Technology
      • 5.3.1.7 Functionality
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Application
      • 5.3.2.4 Form
      • 5.3.2.5 End User
      • 5.3.2.6 Technology
      • 5.3.2.7 Functionality
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Application
      • 5.3.3.4 Form
      • 5.3.3.5 End User
      • 5.3.3.6 Technology
      • 5.3.3.7 Functionality
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Application
      • 5.4.1.4 Form
      • 5.4.1.5 End User
      • 5.4.1.6 Technology
      • 5.4.1.7 Functionality
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Application
      • 5.4.2.4 Form
      • 5.4.2.5 End User
      • 5.4.2.6 Technology
      • 5.4.2.7 Functionality
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Application
      • 5.4.3.4 Form
      • 5.4.3.5 End User
      • 5.4.3.6 Technology
      • 5.4.3.7 Functionality
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Application
      • 5.4.4.4 Form
      • 5.4.4.5 End User
      • 5.4.4.6 Technology
      • 5.4.4.7 Functionality
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Application
      • 5.4.5.4 Form
      • 5.4.5.5 End User
      • 5.4.5.6 Technology
      • 5.4.5.7 Functionality
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Application
      • 5.4.6.4 Form
      • 5.4.6.5 End User
      • 5.4.6.6 Technology
      • 5.4.6.7 Functionality
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Application
      • 5.4.7.4 Form
      • 5.4.7.5 End User
      • 5.4.7.6 Technology
      • 5.4.7.7 Functionality
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Application
      • 5.5.1.4 Form
      • 5.5.1.5 End User
      • 5.5.1.6 Technology
      • 5.5.1.7 Functionality
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Application
      • 5.5.2.4 Form
      • 5.5.2.5 End User
      • 5.5.2.6 Technology
      • 5.5.2.7 Functionality
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Application
      • 5.5.3.4 Form
      • 5.5.3.5 End User
      • 5.5.3.6 Technology
      • 5.5.3.7 Functionality
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Application
      • 5.5.4.4 Form
      • 5.5.4.5 End User
      • 5.5.4.6 Technology
      • 5.5.4.7 Functionality
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Application
      • 5.5.5.4 Form
      • 5.5.5.5 End User
      • 5.5.5.6 Technology
      • 5.5.5.7 Functionality
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Application
      • 5.5.6.4 Form
      • 5.5.6.5 End User
      • 5.5.6.6 Technology
      • 5.5.6.7 Functionality
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Application
      • 5.6.1.4 Form
      • 5.6.1.5 End User
      • 5.6.1.6 Technology
      • 5.6.1.7 Functionality
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Application
      • 5.6.2.4 Form
      • 5.6.2.5 End User
      • 5.6.2.6 Technology
      • 5.6.2.7 Functionality
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Application
      • 5.6.3.4 Form
      • 5.6.3.5 End User
      • 5.6.3.6 Technology
      • 5.6.3.7 Functionality
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Application
      • 5.6.4.4 Form
      • 5.6.4.5 End User
      • 5.6.4.6 Technology
      • 5.6.4.7 Functionality
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Application
      • 5.6.5.4 Form
      • 5.6.5.5 End User
      • 5.6.5.6 Technology
      • 5.6.5.7 Functionality
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Phibro Animal Health
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Eco Animal Health
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Huvepharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Norbrook Laboratories
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 HIPRA
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Vetoquinol
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Ceva Animal Health
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Kyoritsu Seiyaku
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dechra Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Zagro
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Virbac
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Biogenesis Bago
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Lohmann Animal Health
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Neogen Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Biovet
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Elanco Animal Health
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Boehringer Ingelheim Vetmedica
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Vetanco
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merial
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bimeda
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us